McLeod HL - Search Results

1

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. Hoskins JM, et al. Among authors: mcleod hl. J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5. doi: 10.1093/jnci/djm115. Epub 2007 Aug 28. J Natl Cancer Inst. 2007. PMID: 17728214

2

Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389.

Hoskins JM, Marsh S, McLeod HL. Hoskins JM, et al. Among authors: mcleod hl. Drug Metab Dispos. 2005 Oct;33(10):1564-5; author reply 1566. doi: 10.1124/dmd.105.005736. Drug Metab Dispos. 2005. PMID: 16166400 No abstract available.

3

Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?

Yen-Revollo JL, Goldberg RM, McLeod HL. Yen-Revollo JL, et al. Among authors: mcleod hl. Clin Cancer Res. 2008 Jan 1;14(1):8-13. doi: 10.1158/1078-0432.CCR-07-1225. Clin Cancer Res. 2008. PMID: 18172246 Review.

4

Irinotecan pharmacogenetics: influence of pharmacodynamic genes.

Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, Paré L, Culverhouse R, McLeod HL, Baiget M. Hoskins JM, et al. Among authors: mcleod hl. Clin Cancer Res. 2008 Mar 15;14(6):1788-96. doi: 10.1158/1078-0432.CCR-07-1472. Clin Cancer Res. 2008. PMID: 18347181

5

Platinum neurotoxicity pharmacogenetics.

McWhinney SR, Goldberg RM, McLeod HL. McWhinney SR, et al. Among authors: mcleod hl. Mol Cancer Ther. 2009 Jan;8(1):10-6. doi: 10.1158/1535-7163.MCT-08-0840. Mol Cancer Ther. 2009. PMID: 19139108 Free PMC article. Review.

6

Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.

Bhushan S, McLeod H, Walko CM. Bhushan S, et al. Clin Colorectal Cancer. 2009 Jan;8(1):15-21. doi: 10.3816/CCC.2009.n.003. Clin Colorectal Cancer. 2009. PMID: 19203892 Review.

7

UGT1A and irinotecan toxicity: keeping it in the family.

Hoskins JM, McLeod HL. Hoskins JM, et al. Among authors: mcleod hl. J Clin Oncol. 2009 May 20;27(15):2419-21. doi: 10.1200/JCO.2008.20.9478. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364959 No abstract available.

8

Nevirapine hypersensitivity reaction: will the real HLA please stand up?

Hoskins JM, Roederer MW, McLeod HL. Hoskins JM, et al. Among authors: mcleod hl. Curr Opin Mol Ther. 2009 Jun;11(3):226-30. Curr Opin Mol Ther. 2009. PMID: 19479655 No abstract available.

9

Influence of ethnicity on pharmacogenetic variation in the Ghanaian population.

Yen-Revollo JL, Van Booven DJ, Peters EJ, Hoskins JM, Engen RM, Kannall HD, Ofori-Adjei D, McLeod HL, Marsh S. Yen-Revollo JL, et al. Among authors: mcleod hl. Pharmacogenomics J. 2009 Dec;9(6):373-9. doi: 10.1038/tpj.2009.28. Epub 2009 Jun 23. Pharmacogenomics J. 2009. PMID: 19546880

10

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.

Hoskins JM, Rosner GL, Ratain MJ, McLeod HL, Innocenti F. Hoskins JM, et al. Among authors: mcleod hl. Pharmacogenomics. 2009 Jul;10(7):1139-46. doi: 10.2217/pgs.09.35. Pharmacogenomics. 2009. PMID: 19604089 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

587 results

Search Page